This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

BioMarin settled a patent dispute with Ascendis Pharma over the achondroplasia drug Yuviwel, converting a competitive threat into a royalty stream. Under the agreement, BioMarin will receive 20% royalties on U.S. Yuviwel sales and 18% in the EU, Brazil, and South Korea through May 2030. While this monetizes competition, BioMarin still faces market pressure from Yuviwel and potential future competitors like BridgeBio's infigratinib.

Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $312

Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $273

Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $327 Price Target

Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $327 price target.

DigitalOcean's CFO Sells Over 35,000 Shares for $3.8 Million After a 241% One-Year Return

DigitalOcean's CFO Matt Steinfort sold 35,151 shares for approximately $3.8 million between September 1-3, 2026. Of these, 25,151 shares were sold to cover tax withholding obligations from RSU vesting, while 10,000 shares were sold under a pre-established Rule 10b5-1 trading plan. The CFO retains over 503,000 shares worth $55.1 million. The stock has surged 241% over the past year, driven by 29% sales growth in Q2 2026 to $281 million, boosted by AI demand.

DigitalOcean Holdings shares are trading higher after Truist Securities initiated coverage on the stock with a Buy rating and announced a $175 price target.